SHUN TAK HOLDINGS LIMITED 信 德 集 團 有 限 公 司 (Incorporated in Hong Kong with limited liability) (Stock Code: 242) 提名委員會 - 職權範圍 信德集團有限公司 (「本公司」) 董事會 (「董事會」) 謹此制定並設立一個提名委 員會 (「提名委員會」) 其職權、責任以及職責如下： 成員 提名委員會應不時由董事會委任。提名委員會應由至少五名成員組成，過半數成員 須為獨立非執行董事，並包括本公司之集團行政主席兼董事總經理和副董事總經理 及至少一名成員為不同性別。提名委員會主席須為獨立非執行董事或董事會主席， 並應由董事會委任。公司秘書（或其代名人）應擔任提名委員會秘書。 職權 提名委員會獲董事會授權按本職權範圍制定及/或調查任何活動，並應獲提供足夠資 源以履行其職責。提名委員會獲授權向任何僱員獲取任何所需資料以執行其職責， 而所有僱員亦需配合提名委員會所提出的要求。 提名委員會獲董事會授權（如有需 要）尋求由本公司付費之獨立專業意見以履行其職責。 會議 提名委員會會議應按工作要求召開。會議的法定人數為三名委員會 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公佈全部或任何部份 內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 SHUN TAK HOLDINGS LIMITED 信 德 集 團 有 限 公 司 （ 於 香 港 註 冊 成 立 之 有 限 公 司 ） （股份代號：242） 網址：http://www.shuntakgroup.com 二零二五年年度業績公佈 本集團業績 信德集團有限公司（「本公司」）董事會（「董事會」）宣佈本公司及其附屬公司（「本集 團」）截至二零二五年十二月三十一日止年度之綜合年度業績。 本年度本公司擁有人應佔綜合虧損為港幣478百萬元（二零二四年：港幣824百萬 元）。擁有人應佔相關溢利（就本集團及其合營投資及聯營公司的投資物業產生之未變 現公平價值變動作出調整後）（已扣除稅項）將為港幣182百萬元（二零二四年：虧損港 幣244百萬元）。每股基本虧損為15.8港仙（二零二四年：27.3港仙）。 股息 董事會不建議就截至二零二五年十二月三十一日止年度派發任何末期股息（二零二四 年：無）。年內董事 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產 生或因倚賴該等內容而引致之任何損失承擔任何責任。 SHUN TAK HOLDINGS LIMITED 信 德 集 團 有 限 公 司 信德集團有限公司（「本公司」）之董事會（「董事會」）謹此宣佈將於二零二六 年三月三十日（星期一）舉行董事會會議，藉以（其中包括）批准刊發本公司及其 附屬公司截至二零二五年十二月三十一日止年度之全年業績公佈，並考慮建議派發 末期股息（如有）。 承董事會命 信德集團有限公司 公司秘書 曾美珠 香港，二零二六年三月十八日 於本公告日期，本公司之執行董事為何超瓊女士、何超鳳女士、何超蕸女士、岑康權先生 及尹顥璠先生；及獨立非執行董事為何厚鏘先生、吳志文先生、葉家祺先生及尤妤心女 士。 (於香港註冊成立之有限公司) (股份代號: 242) 網址: http://www.shuntakgroup.com 董事會會議日期 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2026年2月28日 | 狀態: 新提交 | | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | 公司名稱: | 信德集團有限公司 | | | 呈交日期: | 2026年3月4日 | | | I. 法定/註冊股本變動 | 不適用 | | FF301 第 1 頁 共 10 頁 v 1.2.0 II. 已發行股份及/或庫存股份變動及足夠公眾持股量的確認 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00242 | 說明 | 普通股 | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | 3,017,661,785 | | | 0 | | 3,017,661,785 | | 增加 / 減少 (-) | ...

Core Viewpoint - ST Bailin (002424) has been placed under risk warning due to false disclosures in its annual reports for the years 2019, 2020, 2021, and 2023, as indicated by the administrative penalty notice from the Guizhou Securities Regulatory Bureau [1] Group 1: Stock Performance - As of February 24, 2026, ST Bailin's stock closed at 4.45 yuan, up 2.06% from the previous trading day, with a total market capitalization of 6.219 billion yuan [1] - The stock opened at 4.39 yuan, reached a high of 4.57 yuan, and a low of 4.37 yuan, with a trading volume of 1.17 billion yuan and a turnover rate of 2.15% [1] Group 2: Regulatory Actions - The company received an administrative penalty notice on December 19, 2025, due to false disclosures in its annual reports [1] - The stock has been under risk warning since December 23, 2025, following the notice from the Guizhou Securities Regulatory Bureau [1] - The company is currently conducting a review of its financial reports for the affected years and is working on corrections and retrospective adjustments [1] Group 3: Company Operations - As of the announcement date, the company's production and operations are reported to be normal [1] - The board of directors is committed to improving the internal control system and enhancing compliance training [1] - The final penalty outcome will be determined by the official decision from the Securities Regulatory Commission [1]

FF301 第 1 頁 共 10 頁 v 1.2.0 II. 已發行股份及/或庫存股份變動及足夠公眾持股量的確認 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00242 | 說明 | 普通股 | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | 3,017,661,785 | | | 0 | | 3,017,661,785 | | 增加 / 減少 (-) | | | 0 | | 0 | | | | 本月底結存 | | 3,017,661,785 | | | 0 | | 3,017,661,785 | 足夠公眾持股量的確認(註4) | 截至月份: | 2026年1月31日 | 狀態: | 新提交 | | --- | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | | 公司名稱: | 信德集團有 ...

Core Viewpoint - ST Bailing (002424) is expected to report significant losses for the year 2025, with net profit forecasts indicating a decline of up to 367.68% compared to the previous year [1][3]. Trading Information Summary - On January 30, ST Bailing's stock closed at 4.23 yuan, with a turnover rate of 1.18% and a trading volume of 143,100 hands, resulting in a transaction amount of 60.4362 million yuan [1]. - The net inflow of main funds was 5.93 million yuan, while retail funds saw a net inflow of 0.2137 million yuan, indicating mixed investor sentiment [1][3]. Performance Disclosure Highlights - ST Bailing forecasts a net profit loss for 2025 ranging from 60 million yuan to 90 million yuan, with a year-on-year decline of 278.46% to 367.68% [1][3]. - The company also anticipates a non-recurring net profit loss between 102 million yuan and 132 million yuan, reflecting a year-on-year decrease of 23.73% to 60.13% [1][3]. - The expected basic earnings per share for 2025 is projected to be between -0.04 yuan and -0.07 yuan [1]. Company Announcement Summary - The decline in ST Bailing's performance is attributed to multiple factors, including a slowdown in market demand, adjustments in medical insurance payment policies, intensified market competition, and rising fixed costs [1][3].

Group 1 - The company ST Bailin (002424.SZ) expects a net profit attributable to shareholders of -90 million to -60 million yuan for 2025, representing a year-on-year decline of 367.68% to 278.46% [1] - The net profit after deducting non-recurring gains and losses is projected to be -132 million to -102 million yuan for 2025 [1] - The overall business operations of the company remain stable, but are impacted by factors such as a slowdown in product market demand, adjustments in medical insurance payment policies, and intensified market competition [1] Group 2 - The company's operating revenue is expected to decline by approximately 20% year-on-year for 2025 [1] - Increased fixed asset scale leads to higher depreciation and amortization expenses, contributing to rising fixed costs that affect current performance [1] - The overall industry is under profit pressure due to changes in supply and demand across the industrial chain and inventory pressures [1]

Core Viewpoint - ST Bailin (002424.SZ) has received a patent application acceptance notice from the National Intellectual Property Administration for a traditional Chinese medicine formulation aimed at treating diabetes and its complications, which will enhance the company's core intellectual property protection [1] Group 1: Patent Application Details - The accepted patent application is for a "traditional Chinese medicine formulation for treating diabetes or its complications," based on years of research from the company's Tang Ning Tong Luo project [1] - The confidentiality protection scope includes formula composition, production processes, and multiple treatment areas, with a confidentiality period aligned with the "secret" confidentiality period under the National Confidentiality Law of the People's Republic of China [1] Group 2: Implications for the Company - The acceptance of this confidential patent will provide comprehensive and tighter core intellectual property protection for the Tang Ning Tong Luo project [1] - If the patent is ultimately granted, it will help the company avoid core technology leakage and accelerate clinical promotion and market transformation, thereby enhancing the company's core competitiveness [1]

Core Viewpoint - The recent announcements from Kelun Pharmaceutical indicate significant changes in institutional holdings, with notable fund managers adjusting their positions, reflecting a mixed sentiment in the market towards the company's future prospects [1] Group 1: Institutional Holdings Changes - Guo Lan, a well-known fund manager from China Europe Fund, reduced holdings in Kelun Pharmaceutical by 1.867 million shares in Q4 2025, following a previous reduction of 2.5371 million shares in Q3 2025 [1] - The Guangfa Multi-Factor Mixed Fund, managed by Tang Xiaobin, also exited the top ten shareholders of Kelun Pharmaceutical by reducing over 10 million shares in Q4 2025 [1] - In contrast, Zhao Bei from ICBC Credit Suisse increased holdings in Kelun Pharmaceutical by 2 million shares in Q4 2025, while the National Social Security Fund's 416 portfolio became a new top ten shareholder with 13.9445 million shares [1] Group 2: Market Sentiment and Future Outlook - Fund managers express optimism about the market, actively seeking investment opportunities, with a focus on sectors like automotive, semiconductors, and specialized equipment [1] - Liu Ankun from Rongtong Fund noted a "short-term active, long-term positive" market characteristic, supported by continuous inflow of incremental funds and strong sectoral performance in AI and non-ferrous metals [1] - The market is expected to continue its upward trend, driven by funding factors and potential catalysts in industries such as semiconductors and commercial aerospace, with a belief that the spring market rally may have already begun [1]